Management of Systemic Lupus Erythematosus (SLE), SLE Arthritis, and SLE Anemia

Overview

I. General/Non-Pharmacological Measures (All Patients)

• Daily sunscreen on sun-exposed areas
• Regular exercise and maintaining normal body weight
• Smoking cessation (tobacco reduces antimalarial efficacy)
• Balanced diet
• Up-to-date vaccinations
• Blood pressure, lipid, and glucose control
• Low-dose aspirin in antiphospholipid antibody (aPL)-positive patients

• Remission: Clinical SLEDAI = 0, on HCQ, prednisone ≤5 mg/day
• Low disease activity state (LLDAS): SLEDAI ≤4, HCQ, prednisone ≤5 mg/day, immunosuppressives at stable tolerated dose

II. Universal Therapy: Hydroxychloroquine (HCQ)

• Reduces disease flares
• Improves overall survival
• Decreases risk of renal disease and accelerated atherosclerosis
• Reduces flares during pregnancy
• Most useful drug for fatigue in SLE
• Safe in pregnancy and breastfeeding

Tobacco use interferes with antimalarial efficacy.

III. Treatment of Non-Renal SLE (By Severity)

Drug Summary by Tier

• MTX (methotrexate): arthritis and skin; folinic acid antagonist
• AZA (azathioprine): skin, arthritis; screen TPMT gene before use
• MMF (mycophenolate mofetil): skin, joints, nephritis; purine synthesis inhibitor
• BEL (belimumab): anti-BAFF biologic; IV or SC; FDA-approved; improves glucocorticoid-sparing
• ANI (anifrolumab): anti-type I IFN receptor; FDA-approved; especially for severe skin disease; NOT for severe neuropsychiatric SLE
• CYC (cyclophosphamide): alkylating agent; IV for severe/organ-threatening disease
• RTX (rituximab): anti-CD20; used in refractory disease

IV. SLE Arthritis - Specific Management

1. HCQ - first-line for all SLE arthritis; highly effective for mild-to-moderate joint disease
2. NSAIDs - adjunctive for pain and inflammation in mild disease; use cautiously (renal/CV risk in SLE)
3. Short-course glucocorticoids (oral or IM) - for flares; minimize duration and taper quickly to ≤5 mg/day prednisone or discontinue
4. Methotrexate (MTX) - particularly effective for arthritis; 7.5-15 mg/week orally; leflunomide is an alternative
5. Azathioprine (AZA) - especially if concomitant skin or hematologic disease
6. MMF - equal option to MTX/AZA for moderate disease
7. Belimumab or anifrolumab - for persistent moderate-to-severe arthritis despite above

Note: MTX, AZA, and MMF are considered equal options for second-line therapy in mild disease and first-line for moderate disease. Ordering does not imply preference.

V. SLE Anemia - Classification and Management

Types of Anemia in SLE

Hematologic Cytopenias Beyond Anemia

• Leukopenia (<4000/µL): Common (~50% of SLE patients); usually lymphopenia (<1500/µL) rather than neutropenia
• Thrombocytopenia (<150,000/µL): Usually mild, immune-mediated; can be severe (<50,000/µL); associated with APS/aPL antibodies

Treatment of SLE Anemia and Cytopenias

• Control the underlying SLE disease activity with HCQ + immunosuppressives
• Iron supplementation only if true concurrent iron deficiency documented

1. Glucocorticoids - prednisone 1 mg/kg/day; first-line
2. Anti-CD20 agents (rituximab) - indicated for lupus-related AIHA and severe thrombocytopenia; FDA-recognized use
3. Azathioprine or MMF - steroid-sparing maintenance
4. IVIG (intravenous immunoglobulin) - for acute, severe hemolysis or thrombocytopenia
5. Splenectomy - reserved for refractory cases

• Glucocorticoids + IVIG (for acute bleeding risk)
• Rituximab for refractory disease
• Platelet growth factors (TPO-RA) for resistant cases
• Splenectomy in resistant cases

• Plasmapheresis + high-dose glucocorticoids (potentially lifesaving)
• Rituximab and the C5 inhibitor eculizumab in refractory atypical HUS

VI. Lupus Nephritis Management

• Initial: MMF (preferred in Black/Hispanic patients) OR low-dose cyclophosphamide + glucocorticoids
• Add-on options: Belimumab (approved 2020) or voclosporin (approved 2021) as triple therapy with MMF + GC
• Maintenance: MMF preferred over AZA for preserving renal function; AZA preferred in pregnancy
• Adjuncts: ACEi/ARB for all class III/IV/V nephritis; SGLT2i if decreased eGFR
• Targets: ≥25% reduction in UPCR at 3 months; ≥50% reduction to <3 g/day at 6 months; <0.5-0.7 g/day at 12-24 months

VII. Pregnancy Considerations

• HCQ: safe and standard of care for all SLE pregnancies; reduces flares
• AZA and tacrolimus: safe in pregnancy
• MMF and MTX: teratogenic - avoid
• Belimumab, anifrolumab, voclosporin: avoid (insufficient safety data)
• Low-dose aspirin: for preeclampsia prevention
• LMWH: for APS-related pregnancy morbidity

VIII. Emerging Therapies (2025)

• Obinutuzumab (anti-CD20 mAb): phase 3 data for lupus nephritis; also being studied in non-renal SLE
• SGLT2 inhibitors: being studied for nephroprotective effects in lupus nephritis
• Iberdomide / KZR-616: novel small molecules targeting immune pathways in trials
• CAR-T therapy targeting autoreactive B and T cells: early-phase trials showing remission in refractory SLE

Recent Evidence (EULAR 2023 Update)